These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 21926299)

  • 1. Trisomic and allelic differences influence phenotypic variability during development of Down syndrome mice.
    Deitz SL; Roper RJ
    Genetics; 2011 Dec; 189(4):1487-95. PubMed ID: 21926299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The "Down syndrome critical region" is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome.
    Belichenko NP; Belichenko PV; Kleschevnikov AM; Salehi A; Reeves RH; Mobley WC
    J Neurosci; 2009 May; 29(18):5938-48. PubMed ID: 19420260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of allelic differences in Down syndrome.
    Roper RJ; Hawley L; Goodlett CR
    Prog Brain Res; 2020; 251():29-54. PubMed ID: 32057311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-trisomic homeobox gene expression during craniofacial development in the Ts65Dn mouse model of Down syndrome.
    Billingsley CN; Allen JR; Baumann DD; Deitz SL; Blazek JD; Newbauer A; Darrah A; Long BC; Young B; Clement M; Doerge RW; Roper RJ
    Am J Med Genet A; 2013 Aug; 161A(8):1866-74. PubMed ID: 23843306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trisomy for the Down syndrome 'critical region' is necessary but not sufficient for brain phenotypes of trisomic mice.
    Olson LE; Roper RJ; Sengstaken CL; Peterson EA; Aquino V; Galdzicki Z; Siarey R; Pletnikov M; Moran TH; Reeves RH
    Hum Mol Genet; 2007 Apr; 16(7):774-82. PubMed ID: 17339268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome.
    McElyea SD; Starbuck JM; Tumbleson-Brink DM; Harrington E; Blazek JD; Ghoneima A; Kula K; Roper RJ
    Hum Mol Genet; 2016 Nov; 25(22):4856-4869. PubMed ID: 28172997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A chromosome 21 critical region does not cause specific Down syndrome phenotypes.
    Olson LE; Richtsmeier JT; Leszl J; Reeves RH
    Science; 2004 Oct; 306(5696):687-90. PubMed ID: 15499018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Embryonic and not maternal trisomy causes developmental attenuation in the Ts65Dn mouse model for Down syndrome.
    Blazek JD; Billingsley CN; Newbauer A; Roper RJ
    Dev Dyn; 2010 Jun; 239(6):1645-53. PubMed ID: 20503361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of trisomy on brain shape and volume in related aneuploid mouse models.
    Aldridge K; Reeves RH; Olson LE; Richtsmeier JT
    Am J Med Genet A; 2007 May; 143A(10):1060-70. PubMed ID: 17431903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skeletal Deficits in Male and Female down Syndrome Model Mice Arise Independent of Normalized Dyrk1a Expression in Osteoblasts.
    Thomas JR; Sloan K; Cave K; Wallace JM; Roper RJ
    Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The power of comparative and developmental studies for mouse models of Down syndrome.
    Moore CS; Roper RJ
    Mamm Genome; 2007 Jul; 18(6-7):431-43. PubMed ID: 17653795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sexually dimorphic DYRK1A overexpression on postnatal day 15 in the Ts65Dn mouse model of Down syndrome: Effects of pharmacological targeting on behavioral phenotypes.
    Hawley LE; Prochaska F; Stringer M; Goodlett CR; Roper RJ
    Pharmacol Biochem Behav; 2022 Jun; 217():173404. PubMed ID: 35576991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased Skin Tumor Incidence and Keratinocyte Hyper-Proliferation in a Mouse Model of Down Syndrome.
    Yang A; Currier D; Poitras JL; Reeves RH
    PLoS One; 2016; 11(1):e0146570. PubMed ID: 26752700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Commonality in Down and fetal alcohol syndromes.
    Solzak JP; Liang Y; Zhou FC; Roper RJ
    Birth Defects Res A Clin Mol Teratol; 2013 Apr; 97(4):187-97. PubMed ID: 23554291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rescue of the abnormal skeletal phenotype in Ts65Dn Down syndrome mice using genetic and therapeutic modulation of trisomic Dyrk1a.
    Blazek JD; Abeysekera I; Li J; Roper RJ
    Hum Mol Genet; 2015 Oct; 24(20):5687-96. PubMed ID: 26206885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal mineralization of the Ts65Dn Down syndrome mouse appendicular skeleton begins during embryonic development in a Dyrk1a-independent manner.
    Blazek JD; Malik AM; Tischbein M; Arbones ML; Moore CS; Roper RJ
    Mech Dev; 2015 May; 136():133-42. PubMed ID: 25556111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Craniofacial phenotypes in segmentally trisomic mouse models for Down syndrome.
    Richtsmeier JT; Zumwalt A; Carlson EJ; Epstein CJ; Reeves RH
    Am J Med Genet; 2002 Feb; 107(4):317-24. PubMed ID: 11840489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
    García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
    Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity-Dependent Dysfunction in Visual and Olfactory Sensory Systems in Mouse Models of Down Syndrome.
    William CM; Saqran L; Stern MA; Chiang CL; Herrick SP; Rangwala A; Albers MW; Frosch MP; Hyman BT
    J Neurosci; 2017 Oct; 37(41):9880-9888. PubMed ID: 28899917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone density phenotypes in mice aneuploid for the Down syndrome critical region.
    Olson LE; Mohan S
    Am J Med Genet A; 2011 Oct; 155A(10):2436-45. PubMed ID: 21915988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.